3 ms·
> at least hundreds of billions of dollars on this very same project. How is that a measure of doing something meaningful ? Take EADS making the Ariane rocket
by ekianjo 11y ago
> at least hundreds of billions of dollars on this very same project.
How is that a measure of doing something meaningful ? Take EADS making the Ariane rocket launchers, they have been spending billions and billions of Euros making rockets for years, yet they have no project like SpaceX and yet they will be rapidly obsolete once SpaceX works as expected.
It's not about the amount you spend, it's about experimenting in new areas not explored yet. Now, about fusion, I have no idea what they plan to do, but in principle there's always new things worth trying (even if they end up failing).
- TeMPOraL 11y agoIt's a measure that there's been a lot of effort going on in the past decades, so it's unlikely that a random startup with minuscule budget will suddenly crack it. SpaceX vs. Airbus Group is a bad example because Elon is only dropping costs of what is a proven technology (rockets). We don't have a break-even fusion reactor yet. But to be honest, I think we need to encourage more effort, so I applaud the project anyway, and keep my fingers crossed.
- ekianjo 11y ago> SpaceX vs. Airbus Group is a bad example because Elon is only dropping costs of what is a proven technology (rockets). I disagree on that point. SpaceX is not just making rockets cheaper, it's changing the paradigm by making rockets re-usable, which is very far from what EADS is planning to do currently. It's a game-changer and will divide the costs of launching something to space by 10 or more. I cant comment on the Fusion startup, but we should not assume that companies operating with billions of cash are more effective at innovation than smaller ones with smaller budgets. They aren't, and that has been proven in many cases, SpaceX is just one good example coming to mind. In the pharma world, very small biotechs with minimal funding are responsible for the discovery of many new drug targets, and not the large pharma groups themselves.